I PROWESS forsøget opstod der alvorlige tilfælde af blødning hos henholdsvis 3, 5% og 2, 0% af de drotrecogin alfa (aktiveret) - behandlede og placebobehandlede patienter i løbet af den 28- dages forsøgsperiode.
Serious bleeding events during the 28-day study period In PROWESS, the incidence of serious bleeding events during the 28-day study period was 3.5% and 2.0% in drotrecogin alfa (activated)-treated and placebo-treated patients, respectively.